MediciNova(NASDAQ) MNOV

Market Cap$65.46M

Since IPO (2006)-88%

5 Year-63%

1 Year+0%

1 Month-6%

$1.34

-0.37%

-0.00Today

MediciNova last closing stock price
Metric	Price	Date
Last close	USD 1.33	2026-07-31

MediciNova stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.76%	USD 1.32	2026-07-24
1 month	-6.34%	USD 1.42	2026-07-01
3 month	-5%	USD 1.40	2026-05-01
Year to date	+1.53%	USD 1.31	2025-12-31
1 year	+0.38%	USD 1.33	2025-07-31
3 year	-43.16%	USD 2.34	2023-08-01
5 year	-63.36%	USD 3.63	2021-07-30
Since inception	-87.85%	USD 10.95	2006-12-07

MediciNova Financials at a Glance

Market Cap

$65.46M

Revenue (TTM)

$596.64K

Net Income (TTM)

-$11.72M

EPS (TTM)

-$0.24

P/E Ratio

-5.57

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$1.34

Volume

8,040.544

Open

$1.35

Price

$1.34

Volume

8,040.544

Open

$1.35

Previous Close

$1.33

Daily Range

$1.33 - $1.35

52-Week Range

$1.17 - $1.96

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$1.34

Volume

8,040.544

Open

$1.35

Previous Close

$1.33

Daily Range

$1.33 - $1.35

52-Week Range

$1.17 - $1.96

Estimated Earnings Date

Aug 13, 2026

MNOV News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MediciNova

MediciNova develops medicines for people with serious diseases lacking good treatment options. Its main products target neurological and fibrotic conditions. The company’s work aims to address needs not met by current therapies.

Pipeline Parade: What MediciNova Makes

MN-166 (ibudilast): Oral drug for neurological diseases like multiple sclerosis and ALS; 0% of revenue.
MN-001 (tipelukast): Oral treatment for fibrotic and metabolic diseases, such as fatty liver disease; 0% of revenue.
MN-221 (bedoradrine): Inhaled medicine for sudden asthma attacks; 0% of revenue.
MN-029 (denibulin): Drug for treating solid tumor cancers; 0% of revenue.
Clinical Research Services: Contract research for clinical trials, mainly for ALS; 100% of revenue in Q2 2025.

Growth Spurts and Strategic Moves

Signed new clinical research agreement with Mayo Foundation in December 2024, services began April 2025.
Entered Standby Equity Purchase Agreement with Yorkville for up to $30 million in July 2025.
Maintains partnerships with Kissei Pharmaceutical, Kyorin Pharmaceutical, Angiogene Pharmaceuticals, and Meiji Seika Kaisha for drug development.
Expanded product pipeline to include treatments for neurological, fibrotic, and cancer indications since 2000.

What Makes MediciNova Stand Out

MediciNova focuses on diseases with few treatment options, using a single-segment business model for efficiency. The company leverages partnerships and external funding to advance its drug pipeline while keeping operations lean.

Five Things You Need to Know

Revenue was $134,599 in Q2 2025, up from $0 in Q2 2024.
All Q2 2025 revenue came from clinical research services, not product sales.
Operating loss was $3.6 million in Q2 2025, up 18.4% year-over-year.
Cash and cash equivalents were $34.3 million as of June 30, 2025, down 15% from December 2024.
Research and development expenses rose 37.5% year-over-year in Q2 2025.

Bottom Line

MediciNova remains focused on developing new drugs for hard-to-treat diseases. The company relies on partnerships and service contracts to support its research pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Yuichi Iwaki, MD, PhD

Website

www.medicinova.com

Headquarters

La Jolla, CA 92037, US

MNOV Financials

Key Financial Metrics (TTM)

Gross Margin

15.20%

Operating Margin

-2164.84%

Net Income Margin

-1964.35%

Return on Equity

-27.29%

Return on Capital

-31.79%

Return on Assets

-27.44%

Earnings Yield

-17.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$65.46M

Shares Outstanding

49.22M

Volume

8.04K

Avg. Volume

44.92K

Financials (TTM)

Gross Profit

$90.68K

Operating Income

-$12.92M

EBITDA

-$11.72M

Operating Cash Flow

-$9.50M

Capital Expenditure

-$10.83K

Free Cash Flow

-$9.51M

Cash & ST Invst.

$27.33M

Total Debt

$165.20K

MediciNova Performance Analysis

MediciNova annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 1,000,000	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 409,657	N/A

MediciNova sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	-8.4%
Q4	2025-12-31	23.0%
Q1	2026-03-31	23.2%

MediciNova annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.29	37.6%
2023	2023-12-31	USD -0.17	-39.1%
2024	2024-12-31	USD -0.23	28.9%
2025	2025-12-31	USD -0.24	8.5%

MediciNova sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-14.6%
Q3	2025-09-30	10.3%
Q4	2025-12-31	8.8%
Q1	2026-03-31	4.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$186.98K

N/A

Gross Profit

$12.62K

N/A

Gross Margin

6.75%

N/A

Market Cap

$65.46M

N/A

Market Cap/Employee

$10.91M

N/A

Employees

N/A

Net Income

-$2.59M

+9.7%

EBITDA

-$2.54M

+11.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$27.33M

-25.3%

Total Debt

$165.20K

-53.5%

Accounts Receivable

$245.10K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$165.20K

-13.0%

Return on Assets

-27.44%

N/A

Return on Invested Capital

-32.61%

N/A

Free Cash Flow

-$3.48M

+8.0%

Operating Cash Flow

-$3.47M

+8.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ACRVAcrivon Therapeutics, Inc. Common Stock

ACRVAcrivon Therapeutics, Inc. Common Stock$1.50-1.32%

XBITXBiotech Inc.

XBITXBiotech Inc.$2.23-0.45%

PMVPPMV Pharmaceuticals, Inc.

PMVPPMV Pharmaceuticals, Inc.$1.11-1.77%

BMEABiomea Fusion, Inc.

BMEABiomea Fusion, Inc.$1.17-4.10%

TCRXTScan Therapeutics, Inc.

TCRXTScan Therapeutics, Inc.$0.74-1.68%

CBUSCibus, Inc.

CBUSCibus, Inc.$1.93+0.00%

FBIOFortress Biotech, Inc.

FBIOFortress Biotech, Inc.$3.13-4.86%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About MNOV

What is the current price of MediciNova?

MediciNova is trading at $1.33 per share.

What is the 52-week range for MediciNova?

Over the past 52 weeks, MediciNova has traded between $1.17 and $1.96.

How much debt does MediciNova have?

As of the most recent reporting period, MediciNova reported total debt of $165.20K.

How much cash does MediciNova have on hand?

MediciNova reported $27.33M in cash and cash equivalents in its most recent financial results.

What is MediciNova’s dividend yield?

MediciNova does not currently have a dividend yield.

MediciNova(NASDAQ) MNOV

MediciNova Financials at a Glance

MNOV News

3 Top Biotech Stocks to Buy Right Now

Why MediciNova Stock Skyrocketed Today

Here's Why MediciNova Is Soaring Today

Why Limelight Networks, MediciNova, and Commvault Systems Jumped Today

Here's Why MediciNova Jumped as Much as 26.2% Today

Here's Why MediciNova, Inc. Stock Is Sliding Today

5 of Last Week's Biggest Winners

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MediciNova

Pipeline Parade: What MediciNova Makes

Growth Spurts and Strategic Moves

What Makes MediciNova Stand Out

Five Things You Need to Know

Bottom Line

MNOV Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MediciNova Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MNOV

What is the current price of MediciNova?

What is the 52-week range for MediciNova?

How much debt does MediciNova have?

How much cash does MediciNova have on hand?

What is MediciNova’s dividend yield?

Premium Investing Services